Whole-body PET/MRI provides one-stop shop for staging high-risk prostate cancer patients

New research shows that molecular imaging–specifically, PSMA PET/MR–performs as well as currently used tools and provides additional information on tumor location that could help guide treatment for prostate cancer patients. The research is featured in the December 2018 issue of The Journal of Nuclear Medicine (http://jnm.snmjournals.org).
Go to Source